These suggested that the PD-1/PD-L1 expression may contribute to a worse clinical outcome in AITL and may be useful as a clinical prognostic indicator to select appropriate therapeutic approaches for individual patients. The gene discussed is PDCD1; the disease is angioimmunoblastic T-cell lymphoma.